Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa exploratory study of two dose levels of R-bambuterol hydrochloride tablets in mild to moderate inflammatory bowel disease
CTR20244653Phase 2Active
- Sponsor
- Kaifa Biopharmaceutical
- Start
- Nov 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bambuterol in inflammatory bowel disease (IBD), autoimmune colitis, Crohn's disease, sponsored by Kaifa Biopharmaceutical. Started Nov 2024; status: active.
02
Drugs
bambuterol
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on CTR20244653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244653.